Lundbeck/Takeda Advance Novel Anxiety Candidate To Phase III
This article was originally published in PharmAsia News
Executive Summary
H. Lundbeck and Takeda Pharmaceutical have initiated Phase III trials of their novel mood and anxiety disorders candidate Lu AA21004 roughly four months after inking a co-development deal, the firms announced Dec. 18
You may also be interested in...
Takeda Weaves Worldwide Web Of Partnerships In Quest For Innovative Drugs, CEO Says
TOKYO - Facing the imminent expiration of American patents on some of its leading drugs, Takeda is building a matrix of partnerships and licensing arrangements in the quest to strengthen its sales of innovative products, according to CEO Yasuchika Hasegawa
Takeda Weaves Worldwide Web Of Partnerships In Quest For Innovative Drugs, CEO Says
TOKYO - Facing the imminent expiration of American patents on some of its leading drugs, Takeda is building a matrix of partnerships and licensing arrangements in the quest to strengthen its sales of innovative products, according to CEO Yasuchika Hasegawa
Lexapro Pediatric Depression Filing Planned In 2008
Forest and H. Lundbeck announced Phase III study results of the SSRI in adolescents aged 12 to 17.